Great job sales Leadership!!
The biopharmaceutical company posted revenue of $1.2 million in the period, which missed Street forecasts. Four analysts surveyed by Zacks expected $1.5 million.
Keryx Biopharma shares have dropped 23 percent since the beginning of the year. The stock has dropped 25 percent in the last 12 months.
